Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cereblon (CRBN)–G1 to S phase transition 1 (GSPT1)–NIMA-related kinase 7 (NEK7)–Sal-like protein 4 (SALL4) neo-substrate complex is a multi-protein assembly formed when molecular glue degraders recruit non-native substrates to the CRL4-CRBN E3 ubiquitin ligase. These neo-substrates share a common structural recognition motif, typically a glycine-rich loop (G-loop) or a specific zinc-finger fold, which allows them to bind the CRBN surface in the presence of small molecules like thalidomide analogs or CC-90009 (Matyskiela et al., 2018; Kozicka et al., 2023). Once the ternary complex is formed, the neo-substrate is polyubiquitinated and subsequently degraded by the 26S proteasome. This mechanism is leveraged in oncology, where the degradation of GSPT1 by CC-90009 induces apoptosis in acute myeloid leukemia (AML) cells (Surka et al., 2021). Additionally, the degradation of NEK7 is being explored as a therapeutic strategy to inhibit the NLRP3 inflammasome in inflammatory diseases. However, the recruitment of SALL4 is primarily associated with the teratogenic side effects of thalidomide, making it a critical off-target to avoid in drug development (Donovan et al., 2018). The study of this complex is central to the field of targeted protein degradation (TPD) and the design of highly selective molecular glues.
Molecular glue-induced recruitment of neo-substrates to the CRL4-CRBN E3 ubiquitin ligase complex, leading to polyubiquitination and subsequent proteasomal degradation.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cereblon (CRBN)–G1 to S phase transition 1 (GSPT1)–NIMA-related kinase 7 (NEK7)–Sal-like protein 4 (SALL4) neo-substrate complex (CRBN–GSPT1–NEK7–SALL4).